Nissan posts 44% drop in quarterly operating profit

February 12, 2026

[
Nissan posts 44% drop in quarterly operating profit
[og_img]
https://www.investing.com/news/stock-market-news/nissan-posts-44-drop-in-quarterly-operating-profit-4501790

Reuters

Montather Rassoul https://thefifthskill.com/

Latest articles

B.Riley initiates Fennec Pharmaceuticals stock with Buy rating, $16 target

European stocks rise as earnings season continues apace; Mercedes disappoints

Quordle hints and answers for Saturday, April 4 (game #1531)

NYT Connections hints and answers for Saturday, April 4 (game #1028)

NYT Strands hints and answers for Saturday, April 4 (game #762)

Dell packs full desktop performance into a palm-sized device that’s powered entirely through a single USB-C connection

Ex-Israeli Intelligence Official: Shockwaves of Trump’s “Take Over Gaza” Heard, Felt Across Region

What UK political parties are promising in the 2019 general election

Otto Warmbier’s parents want North Korea to suffer for their son’s death

Could a ‘youthquake’ cause Boris Johnson to lose the general election?

‘Spaceballs’ Sequel Gets April 2027 Release Date

Joseph Duggar, Wife Kendra Duggar Reunite After Arrests

Celebrities at Women’s Final Four

Season 2 of Netflix’s Best Action Thriller Is Officially Out, and It’s the Perfect Weekend Binge

Form 13D/A The New Germany Fund For: 3 April

Turtle Cameron, Spyre Therapeutics CEO, sells $739k in shares

Fold Holdings CEO Reeves sells $6.9k in shares

Spyre therapeutics CFO sells $370k in shares

The YouTuber who has become one of Gen Z’s most beloved celebrities

26 last-minute holiday gifts that are still thoughtful and unique

Practicing gratitude regularly can make you less stressed and sleep better

8 things millennials wish you would just stop getting them for the holidays

Nissan posts 44% drop in quarterly operating profit

‘Spaceballs’ Sequel Gets April 2027 Release Date

Form 13D/A The New Germany Fund For: 3 April

Joseph Duggar, Wife Kendra Duggar Reunite After Arrests

Turtle Cameron, Spyre Therapeutics CEO, sells $739k in shares